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Reproductive risk factors such as nulliparity, early menarchy and late menopause reflect a well-
established association between estrogen exposure and breast cancer risk over time. However, not all 
epidemiological evidence supports this link: In the post-menopausal period for example, estrogen only 
hormone replacement therapy (HRT) actually appears to reduce breast cancer risk.1 Is it therefore 
possible that in a proportion of women estrogen is protective, and a more nuanced understanding of 
breast cancer pathogenesis is now required? 
In this regard, examining the role of miRNAs during tumor initiation and progression has provided 
valuable insight.2 Recently it has emerged that single nucleotide polymorphisms (SNPs) within miRNA 
binding sites of protein coding genes (miRSNPs) may be important predisposing factors to malignant 
transformation.3 In breast, a miRSNP which disrupts let-7 binding at the KRAS 3’UTR, is associated with 
increased overall cancer risk and in particular, Estrogen Receptor negative (ER–ve) disease.4 This KRAS-
variant allele is also highly prevalent in women with ovarian cancer diagnosed in the post-menopausal 
period and appears to mediate alternative and seemingly paradoxical cellular responses to exogenous 
factors such as chemotherapy drugs.5   
This combination of clinical observations led McVeigh and colleagues to investigate how estrogen might 
impact breast cancer risk and tumor biology for individuals with the KRAS-variant allele.6 In their study, 
1712 women with histologically confirmed breast cancer provided saliva samples for KRAS-genotyping 
and completed questionnaires regarding their reproductive history, use of HRT and personal and family 
history of cancer. Control samples were provided by women who carried the KRAS-variant allele but 
were unaffected by cancer. 
KRAS-variant patients were no more likely than others to have a family history of breast or ovarian 
cancer however, they were more likely to have previously undergone oophorectomy or to have relatives 
diagnosed with multiple primary cancers. Furthermore, it emerged that triple-negative breast cancer 
(TNBC) was significantly more common in post-menopausal women with KRAS-variant. Notably, the risk 
of TNBC was particularly elevated in patients who had previously but were no longer using HRT, 
compared with current users and never users. Past-HRT users with the KRAS-variant were almost 5 
times more likely to be diagnosed with TNBC than past-HRT users with non-variant KRAS status; and the 
tumors were generally of a higher grade. Amongst past-HRT users, patients with non-variant KRAS were 
more likely to have ER+ve disease than KRAS-variant patients, and in current and never-user HRT 
groups, KRAS genotype was not significantly associated with tumor receptor status.  
The authors therefore speculated that HRT withdrawal may differentially impact on the subtype and 
grade of breast cancer depending on KRAS genotype and interrogated their hypothesis by subjecting 
non-malignant mammary cells to estrogen depletion. Importantly, KRAS-variant isogenic cells 
underwent transformation on estrogen withdrawal, an effect which was reversed by reintroduction of 
estrogen to culture media.  
When considered together, this evidence raises the possibility that stopping HRT in the post-
































have KRAS-variant status and/or a previous breast cancer diagnosis. Although this theme was not fully 
explored, McVeigh and colleagues did establish that KRAS-variant patients exhibit an increased risk of 
developing multiple primary breast cancers (MPBC) in tandem (synchronous tumors) and over time 
(metachronous tumors).  
The clinical implications of these findings are as follows: Firstly, knowledge of KRAS-variant status may 
help identify a subset of breast cancer patients at high risk of MPBC who might benefit from more 
intensive investigation and follow-up. Secondly, as estrogen receptor antagonism is a common 
component of adjuvant therapy regimes for breast cancer, it is essential to better define the risks 
associated with KRAS-variant status to ensure the seeds of future malignancies are not sewn during 
treatment for the index cancer.   
On a broader point, more detailed understanding of the molecular underpinnings of cancer may 
enhance drug development programs and further encourage a shift towards personalized treatment 
choices. In this respect the current study resonates with previous research which established the link 
between cetuximab resistance and KRAS mutation status, and changed clinical practice in colorectal 
cancer.7 With this precedent in mind and with further research, miRNA binding site polymorphisms, 
which appear to be promising markers of cancer risk and treatment efficacy, may prove to have 




































1. Anderson GL, et al. Jama 2004; 291:1701-12. 
2. Eastlack SC, et al. Non-Coding RNA 2015; 1:17-43. 
3. Nicoloso MS, et al. Cancer research 2010; 70:2789-98. 
4. Paranjape T, et al. The Lancet Oncology 2011; 12:377-86. 
5. Cipollini M, et al. Pharmacogenomics and personalized medicine 2014; 7:173-91. 
6. McVeigh T, et al. Cell Cycle. 2015. 





































Figure 1: Summary of breast cancer associated SNPs at putative miRNA binding sites; adapted from 
Cipollini et al.5 
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